PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2020; 120(05): 737-746
DOI: 10.1055/s-0040-1709521
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B

Manuel Carcao
1   Division of Haematology/Oncology, Department of Paediatrics and Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
,
Susan Kearney
2   Center for Bleeding and Clotting Disorders, Children's Hospital of Minnesota, Minneapolis, Minnesota, United States
,
Meng Yao Lu
3   Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
,
Masashi Taki
4   Department of Pediatrics, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan
,
Daniel Rubens
5   Novo Nordisk A/S, Søborg, Denmark
,
Chunduo Shen
5   Novo Nordisk A/S, Søborg, Denmark
,
Elena Santagostino
6   Foundation IRCCS Cá Granda, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Maggiore Hospital Policlinico, Milan, Italy
› Institutsangaben Funding This trial was sponsored by Novo Nordisk A/S (Bagsværd, Denmark).
Weitere Informationen

Publikationsverlauf

11. Oktober 2019

20. Februar 2020

Publikationsdatum:
05. Mai 2020 (online)

   Lizenzen und Reprints

Abstract

Long-term safety and efficacy data of extended half-life factor IX (FIX) prophylaxis in children with hemophilia B (HB) are sparse. paradigm 5 is a multinational, open-label, single-arm, phase III trial assessing once-weekly (40 IU/kg) prophylactic nonacog beta pegol (N9-GP) in previously treated patients (PTPs) aged ≤ 12 years with HB (FIX activity ≤ 2%). Primary endpoint: incidence of anti-FIX inhibitory antibodies (≥ 0.6 Bethesda Units). We present a 5-year analysis (N = 25, including remaining patients with ≥ 5 years' follow-up) and compare with a 1-year analysis (≥ 52 weeks' exposure). The main phase enrolled 25 children; 22 entered the extension phase; 17 remained in trial at data cutoff. Median treatment period: 5.6 years/patient; median total number of N9-GP exposure days: 290.0/patient. No patients developed anti-FIX inhibitory antibodies. No other safety concerns, including thromboembolic events, were reported. Neurological examinations have not revealed any new abnormal findings. Sixteen (64.0%) patients remained free from spontaneous bleeds; all bleeds were mild/moderate in severity; 93.0% were controlled with 1 to 2 N9-GP injections. No intracranial hemorrhages were reported. Annualized bleeding rates (ABRs) were very low at 5 years (median/Poisson-estimated mean overall ABR: 0.66/0.99), having decreased from the 1-year analysis (1.00/1.44). Median/Poisson-estimated mean spontaneous ABRs for the 1- and 5-year analyses: 0.00/0.45 and 0.00/0.33. Mean FIX trough activity at 5 years: 17.9%. Mean polyethylene glycol plasma concentration reached steady state at 6 months, increasing slightly over time, in line with increased FIX trough activity. N9-GP administered for ≥ 5 years shows favorable long-term safety and efficacy in PTPs with HB (FIX activity ≤ 2%).

Keywords

N9-GP - hemophilia B - extended half-life - long-term safety - pediatric clinical trial

Supplementary Material

 

  • References

  • 1 Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol 2018; 11 (08) 673-683
    CrossrefPubMedGoogle Scholar
  • 2 Witmer C, Pressley R, Kulkarni R. , et al. Intracranial hemorrhage in patients with hemophilia in the prophylaxis era. Blood 2008; 112 (11) 3388-3388
    CrossrefPubMedGoogle Scholar
  • 3 Pencharz PB. Drug dosing in children–special considerations. Haemophilia 2006; 12 (04) 30-32
    PubMedGoogle Scholar
  • 4 World Federation of Hemophilia. 2012. Guidelines for the management of hemophilia. Available at: http://www1.wfh.org/publications/files/pdf-1472.pdf . Accessed July 22, 2019
    PubMed
  • 5 National Hemophilia Foundation. 2016 . MASAC Recommendation Concerning Prophylaxis. Available at: https://www.hemophilia.org/sites/default/files/document/files/241Prophylaxis.pdf . Accessed July 22, 2019
    PubMed
  • 6 Ljung R. Aspects of prophylactic treatment of hemophilia. Thromb J 2016; 14 (Suppl 1): 30
    CrossrefPubMedGoogle Scholar
  • 7 Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7 (04) 392-396
    CrossrefPubMedGoogle Scholar
  • 8 Santagostino E, Mancuso ME. Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus 2008; 6 (Suppl. 02) s12-s16
    PubMedGoogle Scholar
  • 9 Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118 (10) 2695-2701
    PubMedGoogle Scholar
  • 10 Collins PW, Young G, Knobe K. , et al; paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124 (26) 3880-3886
    PubMedGoogle Scholar
  • 11 Young G, Collins PW, Colberg T. , et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res 2016; 141: 69-76
    CrossrefPubMedGoogle Scholar
  • 12 Escobar MA, Tehranchi R, Karim FA. , et al. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia 2017; 23 (01) 67-76
    CrossrefPubMedGoogle Scholar
  • 13 Carcao M, Zak M, Abdul Karim F. , et al. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. J Thromb Haemost 2016; 14 (08) 1521-1529
    CrossrefPubMedGoogle Scholar
  • 14 Garcês S, Demengeot J, Canas-da-Silva J. , et al. AB1297 bridging ELISA as a screening assay to monitor immunogenicity in routine clinical practice. Ann Rheum Dis 2013; 71 (Suppl. 03) 711
    CrossrefPubMedGoogle Scholar
  • 15 Lin AV. Direct ELISA. Methods Mol Biol 2015; 1318: 61-67
    PubMedGoogle Scholar
  • 16 European Medicines Agency. Guideline on clinical investigation of recombinant and human plasma-derived factor IX products; Accessed July 22, 2019
    PubMed
  • 17 Sternebring O, Gabel-Jensen C, Jacobsen H, Benie AJ, Bjørnsdottir I. Steady-state plasma concentrations of polyethylene glycol (PEG) are reached in children and adults during once-weekly prophylactic treatment with nonacog beta pegol (N9-GP). BioDrugs 2019; 33 (06) 673-681
    CrossrefPubMedGoogle Scholar
  • 18 Stidl R, Denne M, Goldstine J, Kadish B, Korakas KI, Turecek PL. Polyethylene glycol exposure with antihemophilic factor (recombinant), PEGylated (rurioctocog alfa pegol) and other therapies indicated for the pediatric population: history and safety. Pharmaceuticals (Basel) 2018; 11 (03) e75
    CrossrefPubMedGoogle Scholar
  • 19 Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16 (03) 460-468
    PubMedGoogle Scholar
  • 20 Urasinski T, Stasyshyn O, Andreeva T. , et al. Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial. Haemophilia 2015; 21 (02) 196-203
    CrossrefPubMedGoogle Scholar
  • 21 Ragni M, Kulkarni R, Pasi J, et al. B-YOND final results confirm established safety, sustained efficacy, and extended dosing interval for up to 4 years of treatment with rFIXFc in previously treated subjects with severe hemophilia B. Paper presented at: ASH 2018
    PubMedGoogle Scholar
  • 22 Kenet G, Chambost H, Male C. , et al; PROLONG-9FP Investigator Study Group. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost 2016; 116 (04) 659-668
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 23 Fischer K, Kulkarni R, Nolan B. , et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol 2017; 4 (02) e75-e82
    PubMedGoogle Scholar